Polymer-based drug-eluting stent treatment extends the time to reintervention for patients with symptomatic femoropopliteal artery disease: clinical evidence and potential economic value

Conclusion: IMPERIAL data suggest initial treatment with Eluvia extends the time patients spend without undergoing reintervention. This extension may be associated with cost savings in relevant time frames.PMID:38606556 | DOI:10.57264/cer-2024-0025

Source: Journal of Comparative Effectiveness Research - April 12, 2024 Category: General Medicine Authors: William A Gray Yoshimitsu Soga Masahiko Fujihara Osamu Iida Anvar Babaev Daizo Kawasaki Thomas Zeller David O'Connor Michael R Jaff Anna M Chavez Stefan M üller-Hülsbeck Source Type: research